Fighting for an AIDS-free generation.
Learn more at pedaids.org/
Elizabeth Glaser Pediatric AIDS Foundation
Loading...
"This partnership has enabled PEPFAR’s progress; it’s a proven, time-tested approach."
In a new piece published in @statnews.com, 8 former CDC directors highlight the importance of #PEPFAR and why the program should be reformed, not dismantled.
www.statnews.com/2026/05/26/p...
New month. Same mission.
#EndAIDS #GenerationZero
"There has been progress, but we can get to zero."
EGPAF's Rhoda Igweta joined AVAC's Mitchell Warren and
Gilead's Michel Joly for a conversation about #Len at the #DevexImpactHouse @ #WHA79.
@devex.com
youtu.be/QbZo_0p9zbM?...
Then, EGPAF's Rhoda Igweta moderated a discussion among the participants on how to drive momentum for triple elimination and ensure every child is born free from these infections.
#WHA79
Earlier today, EGPAF joined BCIU, @unaids.org, and Abbott for a high-level side event at #WHA79 all about #TripleElimination of HIV, Syphilis, and Hepatitis B.
EGPAF's Dr. Roland van der Ven spoke about country-level best practices and discussed technological advances in diagnostics, treatment, and integration of EMTCT services.
#WHA79
Need something to smile about?
Read Hosiana and Angel's story.
#ECD #GlobalHealth
https://pedaids.org/2026/04/30/from-silence-to-laughter/
Achieving triple elimination demands innovative partnerships between governments, the private sector, and civil society to scale integrated solutions and strengthen health systems.
We are grateful to all the leaders who joined us for this important convening.
#WHA79
Yesterday, Team EGPAF was on Capitol Hill with @gappdc.bsky.social to advocate for this lifesaving program. Continued bipartisan support is essential to protect progress and finally achieve the end of AIDS.
#GlobalHealth #ProudofPEPFAR
"We are starting to rebuild again, and we have no choice."
EGPAF's Rhoda Igweta joined @avac.org and Gilead Sciences for a conversation with @devex.com on the sidelines of #WHA79 about the promise and pitfalls of lenacapavir.
www.devex.com/news/the-pro...
Lenacapavir, the new HIV prevention drug from Gilead Sciences, is both a potential game changer and a high-stakes test of the costs of global health funding cuts.
